paclitaxel has been researched along with Cardiac Diseases in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (19.35) | 18.2507 |
| 2000's | 34 (54.84) | 29.6817 |
| 2010's | 13 (20.97) | 24.3611 |
| 2020's | 3 (4.84) | 2.80 |
| Authors | Studies |
|---|---|
| Cassali, GD; da Silva, CD; de Barros, ALB; Lempek, MR; Melo, MM; Oliveira, MC; Roque, MC | 1 |
| Colleoni, M; Demetriou, GS; Fujiwara, Y; Hanes, V; Kolberg, HC; Santi, P; Tesch, H; Tomasevic, Z | 1 |
| Alves, VD; Carla-da-Silva, J; Dichi, I; Herrera, ACSA; Kern, R; Malanowski, J; Micheletti, PL; Panis, C; Rech, D; Scandolara, TB; Simão, ANC; Souza, JAO; Victorino, VJ | 1 |
| Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Im, DJ; Kim, JY; Kim, YJ; Lee, HJ; Suh, YJ | 1 |
| Darrieux, FCDC; Hachul, DT; Hajjar, LA; Sacilotto, L; Scanavacca, MI; Veronese, C; Veronese, P; Wu, TC | 1 |
| Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M | 1 |
| Ali, ZA; Ben-Yehuda, O; Gkargkoulas, F; Gore, AK; Konigstein, M; Madhavan, MV; Maehara, A; McAndrew, T; Mehdipoor, G; Rahim, HM; Redfors, B; Shlofmitz, E; Srdanovic, I; Stone, GW | 1 |
| Boudou, N; Carrié, D; Chevalier, B; Darremont, O; Dumonteil, N; Garot, P; Harb, T; Lefèvre, T; Leymarie, JL; Louvard, Y; Morice, MC; Moynagh, A; Salvatella, N | 1 |
| Baselga, J; Bellet, M; Blasco, C; Garcia-Martínez, E; Gil-Gil, MJ; Llombart, A; Manso, L; Martinez-Jáñez, N; Melé, M; Mesia, C; Morales, S; Ojeda, B; Pernas, S; Villagrasa, P | 1 |
| Baselga, J; Benavides, M; Cirera, L; Climent, MA; Cortes, J; Cortés-Funes, H; Di Cosimo, S; Dorado, JF; Gascón, P; Gil, M; Lluch, A; Mayordomo, JI; Ojeda, B; Regueiro, P; Rodríguez, CA; Trigo, JM; Vazquez, J | 1 |
| Baim, DS; Chhabra, A; Cox, DA; Dawkins, KD; Haas, RC; Lasala, JM; Lewis, SJ; Mascioli, SR; Schweiger, MJ; Starzyk, RM; Tadros, PN; Untereker, WJ | 1 |
| Chen, C; Come, S; Dang, CT; Dickler, M; Godfrey, L; Hudis, CA; Lin, N; McArthur, HL; Morris, PG; Moy, B; Norton, L; Nulsen, B; Rugo, H; Steingart, R; Sugarman, S; Traina, T; Winer, E | 1 |
| Campos, C; Cano, M; Carballo, M; Costa, JR; Costa, RA; Maldonado, G; Moreira, AC; Pavanello, R; Sousa, A; Sousa, JE | 1 |
| Bear, HD; Di, X; Gennings, C; Gewirtz, DA; Graham, LJ; Sheth, CM; White, KL | 1 |
| Bocksch, W; Boxberger, M; Degenhardt, R; Horstkotte, D; Nienaber, C; Schneider, H; Unverdorben, M; Vallbracht, C; Wiemer, M | 1 |
| Bae, JH; Chae, IH; Chae, JK; Chae, SC; Cho, MC; Cho, Y; Choi, DJ; Chung, WY; Hong, TJ; Hur, SH; Jang, YS; Jeong, KT; Jeong, MH; Kim, DI; Kim, HS; Kim, MJ; Kim, YJ; Lee, MY; Oh, SK; Park, KS; Park, KW; Park, SK; Rha, SW; Seo, WW; Seong, IW; Yang, HM; Yoon, JH | 1 |
| Nagykálnai, T | 1 |
| Miller, KD; O'Neill, A; Perez, EA; Seidman, AD; Sledge, GW | 1 |
| Ostański, M; Sońta-Jakimczyk, D | 1 |
| Ferrero, JM; Foa, C; Largillier, R; Magné, N; Namer, M | 1 |
| Capri, G; Cresta, S; Gianni, L; Grasselli, G; Minotti, G; Perotti, A | 1 |
| Rivera, E | 1 |
| Baran, I; Coskun, H; Demiray, M; Evrensel, T; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Turan, OF; Zarifoglu, M | 1 |
| Corey, B; Savarese, DM; Savy, G; Vahdat, L; Wischmeyer, PE | 1 |
| Davutoglu, V; Soydinc, S | 1 |
| Buyukberber, S; Camci, C; Sevinc, A | 1 |
| Dawkins, F; Hasan, SP; Kamineni, P; Prakasa, K; Ravi, A | 1 |
| Hudis, C; Keefe, D; Lieberman, G; Paton, V; Seidman, A; Tripathy, D | 1 |
| Bighin, C; Catzeddu, T; Del Mastro, L; Fratino, L; Maggi, E; Manzione, L; Marenco, D; Perrone, F; Repetto, L; Rosso, R; Venturini, M; Venturino, A; Zagonel, V | 1 |
| Arsovski, O; Debourdeau, P; Gligorov, J; Lotz, JP | 1 |
| Smorenburg, CH; ten Tije, AJ | 1 |
| Brown, AM; Bryant, J; Dakhil, SR; Davidson, NE; Fehrenbacher, L; Geyer, CE; Ingle, JN; Jenkins, RB; Kaufman, PA; Klein, PM; Kutteh, LA; Lingle, WL; Mamounas, EP; Martino, S; Paik, S; Perez, EA; Pisansky, TM; Romond, EH; Suman, VJ; Swain, SM; Tan-Chiu, E; Visscher, DW; Vogel, VG; Wolmark, N; Yothers, G | 1 |
| Han, KH; Hong, MK; Jang, JS; Kim, JJ; Kim, YH; Lee, BK; Lee, CW; Park, DW; Park, SJ; Park, SW | 1 |
| de Korte, MA; de Vries, EG; Gietema, JA; Jager, PL; Jonkman, S; Kosterink, JG; Lub-De Hooge, MN; Perik, PJ; Sleijfer, DT; van der Graaf, WT; van Veldhuisen, DJ | 1 |
| Abu-Khalaf, MM; Burtness, BA; Chung, GG; DiGiovanna, MP; Haffty, B; Juneja, V; Lee, FA; McGurk, M; Reiss, M; Sipples, R; Wackers, FJ; Zelterman, D | 1 |
| Kanjanavanit, R; Kietpeerakool, C; Srisomboon, J; Suprasert, P; Tiyayon, J | 1 |
| Alberola, V; Albert, A; Campos, JM; Caranyana, V; Juan, O; Muñoz, J | 1 |
| Garg, S; Gevorkian, N; Kent, KM; Okabe, T; Pichard, AD; Roy, P; Satler, LF; Slottow, TL; Smith, K; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R; Xue, Z | 1 |
| Ewer, MS; O'Shaughnessy, JA | 1 |
| Bafaloukos, D; Bakogiannis, C; Bamias, A; Boukovinas, I; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Makatsoris, T; Nicolaides, C; Samantas, E; Skarlos, D; Syrigos, K; Xiros, N | 1 |
| Hochster, H; Speyer, J; Wasserheit, C | 1 |
| Armand, JP; de Forni, M | 1 |
| Adams, J; Arbuck, SG; Christian, M; Gibbs, H; McGuire, W; Oakes, M; Reed, E; Rowinsky, E; Strauss, H; Suffness, M | 1 |
| Lubejko, BG; Sartorius, SE | 1 |
| Catimel, G; Chazard, M; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Soler-Michel, P; Spielmann, M | 1 |
| Baldini, E; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Dell'Anna, R; Gennari, A; Gentile, A; Innocenti, F; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Chan, S | 1 |
| Perez, EA | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 1 |
| Canfield, VA; Geyer, CE; Goodwin, DK; Green, SJ; Martino, S; Meyers, FJ; Moinpour, CM; O'Sullivan, J; Osborne, CK | 1 |
| Asmar, L; Booser, DJ; Buzdar, AU; Fraschini, G; Frye, D; Gibbs, H; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS; Willey, J | 1 |
| Angeles, C; Barnadas, A; Casado, A; Colomer, R; Lluch, A; Maroto, P; Massuti, B; Ojeda, B | 1 |
| Bajamonde, A; Baselga, J; Eiermann, W; Fleming, T; Fuchs, H; Leyland-Jones, B; Norton, L; Paton, V; Pegram, M; Shak, S; Slamon, DJ; Wolter, J | 1 |
| Dieras, V; Perez, E; Valero, V | 1 |
| Pagani, O; Trudeau, M | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Beuzeboc, P; Diéras, V; Laurence, V; Pierga, JY; Pouillart, P | 1 |
| Friedrich, MJ | 1 |
| Buzdar, AU; Forman, AD; Frye, DK; Holmes, FA; Hortobagyi, GN; Newton, LK; Raber, MN; Theriault, RL; Walters, RS | 1 |
| Bailey, KL; Morgan, S; Njaa, BL; Schumpert, M; Sula, MJ | 1 |
14 review(s) available for paclitaxel and Cardiac Diseases
| Article | Year |
|---|---|
[Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasms; Paclitaxel; Taxoids; Trastuzumab | 2010 |
[Cardiac tolerance of the combination paclitaxel-anthracyclines in the context of the management of cancer of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Doxorubicin; Female; Heart; Heart Diseases; Humans; Paclitaxel | 2003 |
Cardiotoxic effects of anthracycline-taxane combinations.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Heart Diseases; Humans; Paclitaxel; Risk; Taxoids | 2003 |
Liposomal anthracyclines in metastatic breast cancer: clinical update.
Topics: Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Doxorubicin; Heart Diseases; Humans; Liposomes; Neoplasm Metastasis; Paclitaxel | 2003 |
Prevention of chemotherapy and radiation toxicity with glutamine.
Topics: Anthracyclines; Antineoplastic Agents; Dietary Supplements; Digestive System; Glutamine; Glutathione; Heart Diseases; Humans; Neoplasms; Paclitaxel; Radiation Injuries | 2003 |
[Cardiac prevention: the oncologic point of view].
Topics: Age Factors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Heart; Heart Diseases; Humans; Liposomes; Paclitaxel; Razoxane; Risk Factors; Trastuzumab | 2004 |
Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2007 |
Cardiotoxicity and cardioprotection during chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Heart; Heart Diseases; Humans; Interleukin-2; Male; Neoplasms; Paclitaxel; Razoxane; Retrospective Studies; Survivors | 1995 |
Cardiotoxicity of chemotherapy.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Fluorouracil; Heart Diseases; Humans; Mice; Mitoxantrone; Neoplasms; Paclitaxel; Prospective Studies; Rabbits; Rats; Razoxane | 1994 |
A reassessment of cardiac toxicity associated with Taxol.
Topics: Animals; Arrhythmias, Cardiac; Female; Heart Diseases; Humans; Myocardial Infarction; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 1993 |
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2001 |
Epirubicin in combination with the taxanes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Epirubicin; Heart Diseases; Humans; Paclitaxel; Taxoids | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Interaction between Herceptin and taxanes.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Heart Diseases; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nervous System Diseases; Neutropenia; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Salvage Therapy; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2001 |
21 trial(s) available for paclitaxel and Cardiac Diseases
| Article | Year |
|---|---|
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Double-Blind Method; Female; Genes, erbB-2; Heart Diseases; Humans; Middle Aged; Paclitaxel; Trastuzumab | 2020 |
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Heart Diseases; Humans; Injections, Subcutaneous; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Stroke Volume; Trastuzumab | 2018 |
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cardiotoxicity; Comorbidity; Cyclophosphamide; Doxorubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Risk Factors; Treatment Outcome | 2015 |
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Genes, erbB-2; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab; Up-Regulation | 2009 |
Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Heart Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Product Surveillance, Postmarketing; Proportional Hazards Models; Prosthesis Design; Registries; Risk Assessment; Time Factors; Treatment Outcome; United States | 2009 |
The paclitaxel-eluting coroflex stent study II (PECOPS II) acute and 6-month clinical and angiographic follow-up, 1-year clinical follow-up.
Topics: Aged; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Female; Follow-Up Studies; Heart Diseases; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Heart Diseases; Humans; Middle Aged; Paclitaxel; Pilot Projects | 2012 |
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytoprotection; Female; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Prospective Studies; Protective Agents | 2003 |
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Heart; Heart Diseases; Heart Failure; Humans; Immunohistochemistry; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Female; Heart Diseases; Humans; Infusions, Intravenous; Neutropenia; Paclitaxel; Survival Analysis | 2005 |
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Diseases; Humans; Mastectomy; Middle Aged; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Recurrence; Survival Analysis; Trastuzumab | 2005 |
Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Comorbidity; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Diseases; Humans; Lung Neoplasms; Male; Multivariate Analysis; Paclitaxel; Patient Compliance; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vascular Diseases | 2007 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cimetidine; Deoxycytidine; Dexamethasone; Diphenhydramine; Female; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ondansetron; Paclitaxel; Premedication; Proportional Hazards Models | 2008 |
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fever; Heart Diseases; Humans; Middle Aged; Neutropenia; Paclitaxel | 1996 |
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Heart Diseases; Humans; Least-Squares Analysis; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies; Stroke Volume; Survival Analysis; Treatment Outcome | 1997 |
Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bacterial Infections; Breast Neoplasms; Cause of Death; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fever; Heart Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia | 1997 |
Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Hypersensitivity; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Middle Aged; Neuromuscular Diseases; Paclitaxel; Pain Measurement; Palliative Care; Survival Analysis; Treatment Failure | 1998 |
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Heart Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Severity of Illness Index; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stroke Volume | 2000 |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2001 |
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Agranulocytosis; Alkaloids; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Drug Evaluation; Female; Heart Diseases; Humans; Methotrexate; Middle Aged; Muscular Diseases; Paclitaxel; Pain; Peripheral Nervous System Diseases; Remission Induction; Soft Tissue Neoplasms; Thrombocytopenia | 1991 |
27 other study(ies) available for paclitaxel and Cardiac Diseases
| Article | Year |
|---|---|
Preclinical toxicological study of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in synergic ratio.
Topics: Action Potentials; Administration, Intravenous; Animals; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Doxorubicin; Drug Compounding; Drug Synergism; Electrocardiography; Female; Heart Diseases; Lethal Dose 50; Lipids; Liposomes; Mice, Inbred BALB C; Myocytes, Cardiac; Paclitaxel | 2021 |
Proinflammatory circulating markers: new players for evaluating asymptomatic acute cardiovascular toxicity in breast cancer treatment.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Doxorubicin; Female; Heart Diseases; Humans; Inflammation Mediators; Middle Aged; Paclitaxel; Trastuzumab | 2021 |
SYNTAX score based on coronary computed tomography angiography may have a prognostic value in patients with complex coronary artery disease: An observational study from a retrospective cohort.
Topics: Aged; Cerebrovascular Disorders; Combined Modality Therapy; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Drug-Eluting Stents; Female; Heart Diseases; Humans; Male; Paclitaxel; Percutaneous Coronary Intervention; Postoperative Complications; Predictive Value of Tests; Prognosis; Retrospective Studies | 2017 |
Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cations; Cyclophosphamide; Doxorubicin; Electrocardiography; Female; Follow-Up Studies; Heart Conduction System; Heart Diseases; Humans; Middle Aged; Natriuretic Peptide, Brain; Paclitaxel; Prospective Studies; Troponin I | 2018 |
Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.
Topics: Antineoplastic Agents; Coronary Restenosis; Drug-Eluting Stents; Everolimus; Female; Heart Diseases; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Proportional Hazards Models; Prospective Studies; Prosthesis Failure; Randomized Controlled Trials as Topic; Time Factors; Treatment Failure | 2019 |
Two-year outcomes of everolimus vs. paclitaxel-eluting stent for the treatment of unprotected left main lesions: a propensity score matching comparison of patients included in the French Left Main Taxus (FLM Taxus) and the LEft MAin Xience (LEMAX) registr
Topics: Aged; Aged, 80 and over; Drug-Eluting Stents; Everolimus; Female; Heart Diseases; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Propensity Score; Registries; Sirolimus; Treatment Outcome | 2013 |
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cardiac Electrophysiology; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart Diseases; Humans; Middle Aged; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Stroke Volume; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2009 |
Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Brazil; Calcinosis; Cardiovascular Agents; Coronary Restenosis; Disease-Free Survival; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heart Diseases; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Risk Assessment; Risk Factors; Sirolimus; Thrombosis; Time Factors; Treatment Outcome | 2010 |
Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Humans; Mice; Mice, Inbred BALB C; Paclitaxel; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Time Factors; Tumor Suppressor Protein p53 | 2010 |
Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chi-Square Distribution; Diabetes Complications; Drug-Eluting Stents; Female; Heart Diseases; Humans; Korea; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Recurrence; Registries; Risk Assessment; Risk Factors; Sirolimus; Time Factors; Treatment Outcome | 2010 |
[Echocardiographic assessment of circulation system in patients during and 3-5 years after all therapy in childhood].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Case-Control Studies; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Echocardiography; Female; Heart Diseases; Humans; Infant; Male; Paclitaxel; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Taxoids; Time Factors; Ventricular Function, Left; Ventricular Function, Right | 2002 |
Paclitaxel treatment article misleading.
Topics: Antineoplastic Agents, Phytogenic; Black or African American; Heart Diseases; Humans; Paclitaxel | 2003 |
Cardiotoxic drugs in breast cancer.
Topics: Black or African American; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; Heart Diseases; Humans; Paclitaxel; Risk Factors | 2004 |
Cardiotoxicities of paclitaxel in African Americans.
Topics: Antineoplastic Agents, Phytogenic; Black or African American; Heart; Heart Diseases; Humans; Paclitaxel; Retrospective Studies; Risk Factors | 2004 |
Advances in taxane therapy for metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow; Breast Neoplasms; Chemistry, Pharmaceutical; Docetaxel; Drug Hypersensitivity; Heart Diseases; Humans; Nausea; Paclitaxel; Taxoids; Treatment Outcome; Vomiting; Water-Electrolyte Imbalance | 2004 |
Reply to "Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)" by L. Del Mastro et al. (Ann Oncol 2005; 16: 253-258).
Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Heart Diseases; Humans; Paclitaxel | 2005 |
Comparison between sirolimus- and Paclitaxel-eluting stents for the treatment of chronic total occlusions.
Topics: Adult; Chronic Disease; Coronary Angiography; Coronary Disease; Coronary Restenosis; Female; Follow-Up Studies; Heart Diseases; Humans; Inpatients; Male; Middle Aged; Paclitaxel; Retrospective Studies; Sirolimus; Stents; Survival Analysis; Treatment Outcome | 2006 |
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Disease Progression; Female; Heart Diseases; Heart Neoplasms; Humans; Indium Radioisotopes; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Metastasis; Paclitaxel; Pentetic Acid; Peptide Fragments; Predictive Value of Tests; Receptor, ErbB-2; Tomography, Emission-Computed, Single-Photon; Trastuzumab; Troponin I | 2006 |
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Heart; Heart Diseases; Humans; Middle Aged; Paclitaxel; Treatment Outcome | 2007 |
Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Electrocardiography; Female; Heart Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Risk Factors | 2006 |
Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies; Heart Diseases; Humans; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Paclitaxel; Prosthesis Design; Reoperation; Secondary Prevention; Sirolimus; Stents; Time Factors; Treatment Outcome | 2007 |
Nursing considerations in paclitaxel (Taxol) administration.
Topics: Alopecia; Drug Hypersensitivity; Drug Interactions; Drug Therapy; Extravasation of Diagnostic and Therapeutic Materials; Gastrointestinal Diseases; Heart Diseases; Humans; Injections, Intravenous; Mouth Mucosa; Neoplasms; Paclitaxel; Patient Care Planning; Stomatitis | 1993 |
Paclitaxel and cardiotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Heart Diseases; Heart Failure; Humans; Paclitaxel; Risk Factors | 1998 |
Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors.
Topics: Aged; Antineoplastic Agents, Phytogenic; Female; Genital Neoplasms, Female; Heart Diseases; Humans; Middle Aged; Paclitaxel; Risk Factors | 1998 |
Doxorubicin/paclitaxel combination does not expose breast cancer patients to excessive cardiac risk.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Heart Diseases; Humans; Paclitaxel | 2001 |
Cardiotoxicity concerns prompt data review in breast cancer trial.
Topics: Advisory Committees; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Heart; Heart Diseases; Humans; Paclitaxel; Receptor, ErbB-2; Statistics as Topic; Trastuzumab | 2002 |
Characterization of cardiac lesions in calves after ingestion of Japanese yew (Taxus cuspidata).
Topics: Animals; Cattle; Cattle Diseases; Fatal Outcome; Gas Chromatography-Mass Spectrometry; Heart Diseases; Histocytochemistry; Plant Poisoning; Taxoids; Taxus | 2013 |